TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific Meeting
The Abstract Selection Committee reviewed thousands of abstracts in advance of the 2019 meeting. Fewer than five percent of accepted abstracts received this distinction for high quality, novel, unique, and interesting research. Dr.
TARGET-IBD is a longitudinal, observational study collecting information from consented patients with inflammatory bowel disease (IBD) to gain insight on the natural course of the disease and treatment outcomes. Data is collected retrospectively for three years from the patient's date of consent and then prospectively for at least five years. The resultant robust cohort allows for the collection of effectiveness and safety data upon new drug approvals.
The study presented at ACG explored patterns of medication use in patients with IBD across the age span, with an elderly focus. Researchers concluded mesalamine was the most common medication used among patients with Crohn's Disease over age 65 and among participants with ulcerative colitis across all age categories, and that patients with Crohn's Disease over age 65 were more than twice as likely to be users of mesalamine at enrollment than patients under age 30. Anti‐tumor necrosis factor alpha (anti‐TNF) use decreased in patients over 65 years versus patients under 30 years for Crohn's Disease and ulcerative colitis.
"TARGET-IBD offers a unique opportunity to examine real-world data and practice patterns across multiple different disease presentations within IBD, including comparisons of patients from different age groups," said
"As TARGET-IBD continues to grow, the potential for its contribution to research in both Crohn's Disease and ulcerative colitis is becoming very clear. We are pleased with the increasing attention surrounding TARGET-IBD," said co-author and TARGET Senior Director of Scientific and Medical Affairs, Dr.
About TARGET PharmaSolutions
TARGET is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners more efficient ways to generate data in real-world settings. For more information, visit www.targetpharmasolutions.com.
CONTACT:
Kayla Slake
[email protected]
984.234.0268 ext. 205
SOURCE
American Financial Group, Inc. Announces the Pricing of $200 Million Aggregate Principal Amount of Subordinated Debentures Due 2059
Callaway residents to receive fines for RV and motor homes
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News